Pyrrolotriazines as ALK and JAK2 inhibitors

US8471005B2 · kind B2 · utility

Assignee

• Cephalon LLC · US

Inventors

• Henry J. Breslin · Lansdale, US
• Sankar Chatterjee · Lansdowne, US
• James L. Diebold · Norristown, US
• Bruce D. Dorsey · Ambler, US
• Derek Dunn · Coatesville, US
• Diane E. Gingrich · Downingtown, US
• Greg A. Hostetler · Newark, US
• Robert L. Hudkins · Chester Springs, US
• Rachael C. Hunter · Princeton, US
• Kurt A. Josef · Wayne, US
• Joseph Lisko · Collegeville, US
• Eugen F. Mesaros · Wallingford, US
• Karen L. Milkiewicz · Exton, US
• Gregory R. Ott · West Chester, US
• Babu G. Sundar · West Chester, US
• Jay Theroff · West Chester, US
• Tho V. Thieu · Ambler, US
• Rabindranath Tripathy · Nazareth, US
• Theodore L. Underiner · Malvern, US
• Linda Weinberg · King of Prussia, US
• Gregory J. Wells · Fairfield, US
• Craig A. Zificsak · Downingtown, US

Key dates

• Filing date: Jun 15, 2011
• Grant date: Jun 25, 2013
• Expiry date: Jun 15, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of formula Ior a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.